(Q44990096)

8 December 2017

title

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study (English)

1 reference

8 December 2017

0 references

1 reference

Sharma AM

1

1 reference

8 December 2017

Wagner T

series ordinal

2

1 reference

8 December 2017

Marsalek P

series ordinal

3

1 reference

8 December 2017

publication date

1 September 2004

1 reference

Journal of Human Hypertension

8 December 2017

published in

1 reference

8 December 2017

volume

18

1 reference

8 December 2017

issue

9

1 reference

8 December 2017

page(s)

669-675

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001676

8 December 2017

exact match

0 references

cites work

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Diabetic and hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Pharmacology of moxonidine: an I1-imidazoline receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

Moxonidine treatment of hypertensive patients with advanced renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

inferred from DOI database lookup

7 January 2021

based on heuristic

Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

inferred from DOI database lookup

7 January 2021

based on heuristic

Hypertension guidelines and their limitations--the impact of physicians' compliance as evaluated by guideline awareness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001676

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.JHH.1001676

1 reference

8 December 2017

1 reference